Structural basis for nonneutralizing antibody competition at antigenic site II of the respiratory syncytial virus fusion protein

Palivizumab was the first antiviral monoclonal antibody (mAb) approved for therapeutic use in humans, and remains a prophylactic treatment for infants at risk for severe disease because of respiratory syncytial virus (RSV). Palivizumab is an engineered humanized version of a murine mAb targeting ant...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Proc Natl Acad Sci U S A
Main Authors: Mousa, Jarrod J., Sauer, Marion F., Sevy, Alexander M., Finn, Jessica A., Bates, John T., Alvarado, Gabriela, King, Hannah G., Loerinc, Leah B., Fong, Rachel H., Doranz, Benjamin J., Correia, Bruno E., Kalyuzhniy, Oleksandr, Wen, Xiaolin, Jardetzky, Theodore S., Schief, William R., Ohi, Melanie D., Meiler, Jens, Crowe, James E.
Formato: Artigo
Idioma:Inglês
Publicado em: National Academy of Sciences 2016
Assuntos:
PNAS Plus
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5098655/
https://ncbi.nlm.nih.gov/pubmed/27791117
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1609449113
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados